Abstract
The labeling of probes with fluorine-18 [18F, β(+); 96.7%] continues to play a considerably important role in the development of positron emission tomography (PET) as a modality for both clinical research and clinical diagnoses. This review summarizes the strategies and recent developments in the fluorine-18 labeling of probes for PET imaging. Problems and issues relating to the practical production of fluorine-18 currently in widespread use are also discussed.
Keywords: Probe, fluorination, F-18, positron emission tomography (PET), molecular imaging, labeling chemistry, radiotracer, radiochemists, radiopharmaceuticals, solid-phase, microfluidics, microwave chemistry
Medicinal Chemistry
Title: Labeling Strategies with F-18 for Positron Emission Tomography Imaging
Volume: 7 Issue: 5
Author(s): Yonghong Gu, Dong Huang, Zhiguo Liu, Jiaguo Huang and Wenbin Zeng
Affiliation:
Keywords: Probe, fluorination, F-18, positron emission tomography (PET), molecular imaging, labeling chemistry, radiotracer, radiochemists, radiopharmaceuticals, solid-phase, microfluidics, microwave chemistry
Abstract: The labeling of probes with fluorine-18 [18F, β(+); 96.7%] continues to play a considerably important role in the development of positron emission tomography (PET) as a modality for both clinical research and clinical diagnoses. This review summarizes the strategies and recent developments in the fluorine-18 labeling of probes for PET imaging. Problems and issues relating to the practical production of fluorine-18 currently in widespread use are also discussed.
Export Options
About this article
Cite this article as:
Gu Yonghong, Huang Dong, Liu Zhiguo, Huang Jiaguo and Zeng Wenbin, Labeling Strategies with F-18 for Positron Emission Tomography Imaging, Medicinal Chemistry 2011; 7 (5) . https://dx.doi.org/10.2174/157340611796799140
DOI https://dx.doi.org/10.2174/157340611796799140 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets An Overview of Targeted Alpha Therapy with <sup>225</sup>Actinium and <sup>213</sup>Bismuth
Current Radiopharmaceuticals Back to the Future: COX-2 Inhibitors for Chemoprevention and Cancer Therapy
Mini-Reviews in Medicinal Chemistry Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Aneuploidy-Inducing Mutations in Mitotic Checkpoint Protein hMad1-Carboxi Terminal Domain Analyzed by SAR and Computational Mutagenesis
Current Proteomics Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Polyphenols and Aging
Current Aging Science ADDENDUM: Increased Akt Signaling Resulting from the Loss of Androgen Responsiveness in Prostate Cancer. Dulinska-Litewka J, McCubrey JA, Laidler P. Curr. Med. Chem., 2013, 20(1), 144-157.
Current Medicinal Chemistry Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Toxicity Burden in Head and Neck Cancer: Past, Present, and Future Strategies
Current Cancer Therapy Reviews Drug Delivery Systems Based on Polymeric Micelles and Ultrasound: A Review
Current Pharmaceutical Design Inhibition of Autophagy by Targeting ATG4B: Promises and Challenges of An Emerging Anti-cancer Strategy
Clinical Cancer Drugs ADAM28 as a Target for Human Cancers
Current Pharmaceutical Design Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Editorial [Hot Topic: ADAMs: Targets for Drug Discovery (Executive Editor: Marcia L. Moss)]
Current Pharmaceutical Design Targeting Hormonal Signaling Pathways in Castration Resistant Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery Combining Drug-Loaded Nanobubbles and Extracorporeal Shock Waves for Difficult-to-Treat Cancers
Current Drug Delivery Integrating the Universe of Effector and Regulatory Immune Cell Subsets: An Emerging Role of Protein-Glycan Interactions
Current Immunology Reviews (Discontinued) Pasireotide - Mechanism of Action and Clinical Applications
Current Drug Metabolism